Restricted accessResearch articleFirst published online 2024-12
Quantification and Correlation Analysis of Bacteroides Species with Diabetes-Related Amino Acids in Individuals with Prediabetes and Type 2 Diabetes Mellitus
The relationship between gut microbiota and diabetes-related amino acids significantly impacts insulin resistance and obesity. We aimed to quantify two Bacteroidetes species and their correlation with branched-chain amino acids, aromatic amino acids, and glutamate in prediabetes (preDM) and type 2 diabetes mellitus (T2DM).
Methods:
Fecal samples were collected from 68 participants, including 21 with T2DM, 23 with preDM, and 24 with normal glycemic tolerance (NGT). The abundance of Bacteroides vulgatus and Bacteroides thetaiotaomicron was determined by quantitative real-time polymerase chain reaction. Plasma amino acid measurements were performed using liquid chromatography coupled with tandem mass spectrometry.
Results:
The quantities of B. vulgatus and B. thetaiotaomicron were reduced in preDM and T2DM than in NGT subjects, but it was not statistically significant. The concentrations of leucine, valine, and tyrosine were significantly higher in preDM and T2DM than in NGT subjects (P < 0.05). A negative correlation was observed between B. thetaiotaomicron abundance and two aromatic amino acids (tyrosine, r = −0.28, P = 0.04; phenylalanine, r = −0.26, P = 0.05).
Conclusions:
These findings imply that, since gut microbiota varies throughout ethnic groups, further research with many participants will be required to determine the abundance of B. vulgatus and B. thetaiotaomicron in preDM and T2DM and their association with diabetes-related amino acids.
TabákAG, HerderC, RathmannW, et al.Prediabetes: A high-risk state for diabetes development. Lancet, 2012; 379(9833):2279–2290; doi: 10.1016/S0140-6736(12)60283-9
3.
LiuR, HongJ, XuX, et al.Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med, 2017; 23(7):859–868; doi: 10.1038/nm.4358
4.
ZhongH, RenH, LuY, et al.Distinct gut metagenomics and metaproteomics signatures in prediabetics and treatment-naïve type 2 diabetics. EBioMedicine, 2019; 47:373–383; doi: 10.1016/j.ebiom.2019.08.048
5.
FanY, PedersenO. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol, 2021; 19(1):55–71; doi: 10.1038/s41579-020-0433-9
6.
LambethSM, CarsonT, LoweJ, et al.Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes, 2015; 2(3):1–7; doi: 10.1543/6/2376-0949.15.031
7.
Chávez-CarbajalA, Pizano-ZárateML, Hernández-QuirozF, et al.Characterization of the gut microbiota of individuals at different T2D stages reveals a complex relationship with the host. Microorganisms, 2020; 8(1):94; doi: 10.3390/microorganisms8010094
8.
CanforaEE, MeexRC, VenemaK, et al.Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol, 2019; 15(5):261–273; doi: 10.1038/s41574-019-0156-z
9.
Safari-AlighiarlooN, EmamiZ, Rezaei-TaviraniM, et al.Gut microbiota and their associated metabolites in diabetes: A cross talk between host and microbes—a review. Metab Syndr Relat Disord, 2023; 21(1):3–15; doi: 10.1089/met.2022.00
10.
LetchumananG, AbdullahN, MarliniM, et al.Gut microbiota composition in prediabetes and newly diagnosed type 2 diabetes: A systematic review of observational studies. Front Cell Infect Microbiol, 2022; 12:943427; doi: 10.3389/fcimb.2022.943427
11.
WuH, EsteveE, TremaroliV, et al.Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med, 2017; 23(7):850–858; doi: 10.1038/nm.4345
12.
MindrescuNM, GujaC, JingaV, et al.Interactions between gut microbiota and oral antihyperglycemic drugs: A systematic review. Int J Mol Sci, 2024; 25(6):3540; doi: 10.3390/ijms25063540
13.
WangTJ, LarsonMG, VasanRS, et al.Metabolite profiles and the risk of developing diabetes. Nat Med, 2011; 17(4):448–453; doi: 10.1038/nm.2307
14.
RamzanI, ArdavaniA, VanweertF, et al.The association between circulating branched chain amino acids and the temporal risk of developing type 2 diabetes mellitus: A systematic review & meta-analysis. Nutrients, 2022; 14(20):4411; doi: 10.3390/nu14204411
15.
WhitePJ, McGarrahRW, HermanMA, et al.Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street. Mol Metab, 2021; 52:101261; doi: 10.1016/j.molmet.2021.101261
16.
FerranniniE, NataliA, CamastraS, et al.Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes, 2013; 62(5):1730–1737; doi: 10.2337/db12-0707
17.
PedersenHK, GudmundsdottirV, NielsenHB, et al.Human gut microbes impact host serum metabolome and insulin sensitivity. Nature, 2016; 535(7612):376–381; doi: 10.1038/nature18646
18.
HooperLV, WongMH, ThelinA, et al.Molecular analysis of commensal host-microbial relationships in the intestine. Science, 2001; 291(5505):881–884; doi: 10.1126/science.291.5505.881
19.
RussellWR, DuncanSH, ScobbieL, et al.Major phenylpropanoid‐derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res, 2013; 57(3):523–535; doi: 10.1002/mnfr.201200594
20.
American Diabetes Association. Standards of medical care in diabetes—2022 abridged for primary care providers. Clin Diabetes, 2022; 40(1):10–38; doi: 10.2337/cd22-as01
21.
MirmiranP, EsfahaniFH, MehrabiY, et al.Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. Public Health Nutr, 2010; 13(5):654–662; doi: 10.1017/S1368980009991698
22.
WuX, MaC, HanL, et al.Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol, 2010; 61(1):69–78.
23.
NewgardCB, AnJ, BainJR, et al.A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab, 2009; 9(4):311–326; doi: 10.1016/j.cmet.2009.02.002
24.
LeiteAZ, RodriguesN, GonzagaMI, et al.Detection of increased plasma interleukin-6 levels and prevalence of Prevotella copri and Bacteroides vulgatus in the feces of type 2 diabetes patients. Front Immunol, 2017; 8:1107; doi: 10.3389/fimmu.2017.01107
25.
EmotoT, YamashitaT, SasakiN, et al.Analysis of gut microbiota in coronary artery disease patients: A possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb, 2016; 23(8):908–921; doi: 10.5551/jat.32672
26.
YoshidaN, EmotoT, YamashitaT, et al.Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation, 2018; 138(22):2486–2498; doi: 10.1161/CIRCULATIONAHA.118.033714
27.
ThingholmLB, RühlemannMC, KochM, et al.Obese individuals with and without type 2 diabetes show different gut microbial functional capacity and composition. Cell Host Microbe, 2019; 26(2):252–264.e10; doi: 10.1016/j.chom.2019.07.004
28.
AhmadA, YangW, ChenG, et al.Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals. PLoS One, 2019; 14(12):e0226372; doi: 10.1371/journal.pone.0226372
29.
RemelyM, HippeB, ZannerJ, et al.Gut microbiota of obese, type 2 diabetic individuals is enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after weight loss. Endocr Metab Immune Disord Drug Targets, 2016; 16(2):99–106.
30.
YeD, HuangJ, WuJ, et al.Integrative metagenomic and metabolomic analyses reveal gut microbiota-derived multiple hits connected to development of gestational diabetes mellitus in humans. Gut Microbes, 2023; 15(1):2154552; doi: 10.1080/19490976.2022.2154552
31.
CuskinF, LoweEC, TempleMJ, et al.Human gut Bacteroidetes can utilize yeast mannan through a selfish mechanism. Nature, 2015; 517(7533):165–169; doi: 10.1038/nature13995
32.
VétizouM, PittJM, DaillèreR, et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015; 350(6264):1079–1084; doi: 10.1126/science.aad1329
33.
WuH, TremaroliV, SchmidtC, et al.The gut microbiota in prediabetes and diabetes: A population-based cross-sectional study. Cell Metab, 2020; 32(3):379–390.e3; doi: 10.1016/j.cmet.2020.06.011
34.
ZhangX, ShenD, FangZ, et al.Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One, 2013; 8(8):e71108; doi: 10.1371/journal.pone.0071108
35.
VangipurapuJ, Fernandes SilvaL, KuulasmaaT, et al.Microbiota-related metabolites and the risk of type 2 diabetes. Diabetes Care, 2020; 43(6):1319–1325; doi: 10.2337/dc19-2533
36.
DengK, XuJ-J, ShenL, et al.Comparison of fecal and blood metabolome reveals inconsistent associations of the gut microbiota with cardiometabolic diseases. Nat Commun, 2023; 14(1):571; doi: 10.1038/s41467-023-36256-y
37.
KrautkramerKA, FanJ, BäckhedF. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol, 2021; 19(2):77–94; doi: 10.1038/s41579-020-0438-4
38.
BarN, KoremT, WeissbrodO, et al.A reference map of potential determinants for the human serum metabolome. Nature, 2020; 588(7836):135–140; doi: 10.1038/s41586-020-2896-2
39.
ChenL, ZhernakovaDV, KurilshikovA, et al.Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome. Nat Med, 2022; 28(11):2333–2343; doi: 10.1038/s41591-022-02014-8
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
